PRA Health Sciences, Inc. (NASDAQ:PRAH)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Group LLC in a research note issued on Thursday. They currently have a $92.00 price objective on the medical research company’s stock, up from their previous price objective of $88.00. Jefferies Group LLC’s target price indicates a potential upside of 24.64% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Citigroup Inc. restated a “buy” rating and set a $93.00 target price (up previously from $90.00) on shares of PRA Health Sciences in a research note on Thursday. SunTrust Banks, Inc. reiterated a “buy” rating on shares of PRA Health Sciences in a research note on Wednesday. Robert W. Baird boosted their price target on shares of PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a research note on Tuesday. BidaskClub cut shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Credit Suisse Group boosted their price target on shares of PRA Health Sciences from $80.00 to $84.00 and gave the stock an “outperform” rating in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $78.00.

PRA Health Sciences (NASDAQ:PRAH) traded down 0.43% on Thursday, reaching $73.81. The company had a trading volume of 1,755,790 shares. The stock’s 50 day moving average price is $75.31 and its 200-day moving average price is $67.06. The stock has a market capitalization of $4.62 billion, a PE ratio of 47.65 and a beta of 0.45. PRA Health Sciences has a 12-month low of $48.42 and a 12-month high of $80.99.

PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Monday, August 7th. The medical research company reported $0.62 earnings per share for the quarter, missing analysts’ consensus estimates of $0.72 by $0.10. PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.88%. The firm had revenue of $457.90 million for the quarter, compared to analysts’ expectations of $447.79 million. During the same quarter last year, the firm posted $0.63 EPS. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Equities analysts expect that PRA Health Sciences will post $3.18 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “PRA Health Sciences, Inc. (NASDAQ:PRAH) Rating Reiterated by Jefferies Group LLC” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.dailypolitical.com/2017/08/10/pra-health-sciences-inc-nasdaqprah-rating-reiterated-by-jefferies-group-llc.html.

Hedge funds have recently made changes to their positions in the company. First Bank & Trust boosted its stake in shares of PRA Health Sciences by 1.6% in the second quarter. First Bank & Trust now owns 3,211 shares of the medical research company’s stock valued at $241,000 after buying an additional 52 shares during the last quarter. Renaissance Group LLC boosted its stake in shares of PRA Health Sciences by 2.5% in the second quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock valued at $393,000 after buying an additional 126 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of PRA Health Sciences by 0.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 21,892 shares of the medical research company’s stock valued at $1,428,000 after buying an additional 140 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after buying an additional 160 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its stake in shares of PRA Health Sciences by 1.9% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock valued at $638,000 after buying an additional 160 shares in the last quarter.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.